Ignite Creation Date:
2024-05-06 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 1:53 PM
Study NCT ID:
NCT04699643
Status:
UNKNOWN
Last Update Posted:
2021-01-07
First Post:
2020-12-29
Brief Title:
FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors
Sponsor:
EverNov Medicines Zhuhai Hengqin Co Ltd
Organization:
EverNov Medicines Zhuhai Hengqin Co Ltd
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-07-30
Start Date Type:
ACTUAL
Primary Completion Date:
2023-06
Primary Completion Date Type:
ESTIMATED
Completion Date:
2023-06
Completion Date Type:
ESTIMATED
First Submit Date:
2020-12-29
First Submit QC Date:
January 5 2021
Study First Post Date:
2021-01-07
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-01-05
Last Update Post Date:
2021-01-07
Last Update Post Date Type:
ACTUAL